ArticleThe Journal of clinical investigation2021
Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Immune responses of lung transplant recipients against SARS-CoV-2 and common respiratory coronaviruses: Evidence for pre-existing cross-reactive immunity.Transplant immunology · 2023Article
- Review
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- COVID-19 after rituximab therapy in cSLE patients.Therapeutic advances in vaccines and immunotherapy · 2023Article
- Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.Signal transduction and targeted therapy · 2022Article
- Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.Transplant immunology · 2022Article
- The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine.Nature communications · 2022Article
- Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions.Translational research : the journal of laboratory and clinical medicine · 2022Review
- SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.PLoS pathogens · 2022Article
- COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients.PloS one · 2022Article
- Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines.Frontiers in immunology · 2022Article
- Progress in kidney transplantation: The role for systems immunology.Frontiers in medicine · 2022Review
- Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study-The COViNEPH Project.Vaccines · 2021Article
- Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients.Transplantation proceedingsArticle
Corrections and comments
- Comment on
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Transplant recipients were excluded from the initial clinical trials determining safety and efficacy of the landmark COVID-19 vaccines. Further, there is increasing evidence that immunosuppressed transplant recipients have a blunted antibody response to COVID-19 vaccination. In a concerning report by Sattler et al. in this issue of the JCI, kidney transplant recipients not only lacked a humoral response following two doses of Pfizer BNT162b2, but also displayed substantial impairment of the cellular response to SARS-CoV-2 antigens. This Commentary addresses potential strategies for transplant providers to evaluate and augment vaccine immunogenicity given the likelihood that COVID-19 will remain a world-wide threat to the health of transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.